Exosome-like Systems: From Therapies to Vaccination for Cancer Treatment and Prevention—Exploring the State of the Art (62 views)
Vaccines, 2024 May; 12: 519-535.
Export to BibTeX Export to EndNote
Paper type: Review Journal Article
Impact factor: 7.8, 5-year impact factor: 7.4
Url: https://doi.org/10.3390/vaccines12050519
Keywords: Exosomes, Cancer Vaccines: Immune System
Affiliations:
*** IBB - CNR ***
References:
1. Available online: https://Gco.Iarc.Fr/Tomorrow/En/Dataviz/Isotype (accessed on 16 February 2024).
2. De Rosa, V.; Iommelli, F.; Monti, M.; Fonti, R.; Votta, G.; Stoppelli, M.P.; Del Vecchio, S. Reversal of Warburg Effect and
Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung
Cancer. Clin. Cancer Res. 2015, 21, 5110–5120.
3. De Rosa, V.; Monti, M.; Terlizzi, C.; Fonti, R.; Del Vecchio, S.; Iommelli, F. Coordinate Modulation of Glycolytic Enzymes and
OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells. Int. J. Mol. Sci. 2019, 20, 3134.
4. Iommelli, F.; De Rosa, V.; Gargiulo, S.; Panico, M.; Monti, M.; Greco, A.; Gramanzini, M.; Ortosecco, G.; Fonti, R.; Brunetti, A.
Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using
3′-Deoxy-3′-[18F]-Fluorothymidine Positron Emission Tomography. Clin. Cancer Res. 2014, 20, 4806–4815.
5. Terlizzi, C.; De Rosa, V.; Iommelli, F.; Pezone, A.; Altobelli, G.G.; Maddalena, M.; Dimitrov, J.; De Rosa, C.; Della Corte, C.M.;
Avvedimento, V.E. ATM Inhibition Blocks Glucose Metabolism and Amplifies the Sensitivity of Resistant Lung Cancer Cell
Lines to Oncogene Driver Inhibitors. Cancer Metab. 2023, 11, 20.
6. De Rosa, V.; Iommelli, F.; Terlizzi, C.; Leggiero, E.; Camerlingo, R.; Altobelli, G.G.; Fonti, R.; Pastore, L.; Del Vecchio, S. NonCanonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER–
Mitochondria Interface in Oncogene-Driven NSCLC. Cancers 2021, 13, 4133.
7. Iommelli, F.; De Rosa, V.; Terlizzi, C.; Fonti, R.; Camerlingo, R.; Stoppelli, M.P.; Stewart, C.A.; Byers, L.A.; Piwnica-Worms, D.;
Del Vecchio, S. A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of
Resistance to Tyrosine Kinase Inhibitors. Cancers 2021, 13, 2022.
8. Iommelli, F.; De Rosa, V.; Terlizzi, C.; Monti, M.; Panico, M.; Fonti, R.; Del Vecchio, S. Inositol Trisphosphate Receptor Type 3-
Mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non–Small Cell Lung Cancer Detected by 18FFluorothymidine. Clin. Cancer Res. 2018, 24, 3126–3136.
9. Mulliri, S.; Laaksonen, A.; Spanu, P.; Farris, R.; Farci, M.; Mingoia, F.; Roviello, G.N.; Mocci, F. Spectroscopic and in Silico
Studies on the Interaction of Substituted Pyrazolo [1, 2-a] Benzo [1, 2, 3, 4] Tetrazine-3-One Derivatives with c-Myc G4-DNA.
Int. J. Mol. Sci. 2021, 22, 6028.
10. Fik-Jaskółka, M.A.; Mkrtchyan, A.F.; Saghyan, A.S.; Palumbo, R.; Belter, A.; Hayriyan, L.A.; Simonyan, H.; Roviello, V.; Roviello,
G.N. Spectroscopic and SEM Evidences for G4-DNA Binding by a Synthetic Alkyne-Containing Amino Acid with Anticancer
Activity. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2020, 229, 117884.
11. Greco, F.; Musumeci, D.; Borbone, N.; Falanga, A.P.; D’Errico, S.; Terracciano, M.; Piccialli, I.; Roviello, G.N.; Oliviero, G.
Exploring the Parallel G-Quadruplex Nucleic Acid World: A Spectroscopic and Computational Investigation on the Binding of
the c-Myc Oncogene Nhe III1 Region by the Phytochemical Polydatin. Molecules 2022, 27, 2997.
12. Marzano, M.; Falanga, A.P.; Marasco, D.; Borbone, N.; D’Errico, S.; Piccialli, G.; Roviello, G.N.; Oliviero, G. Evaluation of an
Analogue of the Marine ε-PLL Peptide as a Ligand of G-Quadruplex DNA Structures. Mar. Drugs 2020, 18, 49.
13. Falanga, A.P.; Terracciano, M.; Oliviero, G.; Roviello, G.N.; Borbone, N. Exploring the Relationship between G-Quadruplex
Nucleic Acids and Plants: From Plant G-Quadruplex Function to Phytochemical G4 Ligands with Pharmaceutic Potential.
Pharmaceutics 2022, 14, 2377.
14. Butterfield, L.H. Cancer Vaccines. BMJ 2015, 350, h988.
15. Tagliamonte, M.; Petrizzo, A.; Tornesello, M.L.; Buonaguro, F.M.; Buonaguro, L. Antigen-Specific Vaccines for Cancer
Treatment. Hum. Vaccines Immunother. 2014, 10, 3332–3346.
Vaccines 2024, 12, 519 14 of 17
16. Zhao, Y.; Baldin, A.V.; Isayev, O.; Werner, J.; Zamyatnin, A.A., Jr.; Bazhin, A. V Cancer Vaccines: Antigen Selection Strategy.
Vaccines 2021, 9, 85.
17. Lyu, C.; Sun, H.; Sun, Z.; Liu, Y.; Wang, Q. Roles of Exosomes in Immunotherapy for Solid Cancers. Cell Death Dis. 2024, 15, 106.
18. Plotkin, S.L.; Plotkin, S.A. A Short History of Vaccination. Vaccines 2012, 4, 1–13.
19. Depelsenaire, A.C.I.; Kendall, M.A.F.; Young, P.R.; Muller, D.A. Introduction to Vaccines and Vaccination. In Micro and
Nanotechnology in Vaccine Development; Elsevier: Amsterdam, The Netherlands, 2017; pp. 47–62.
20. Yadav, D.K.; Yadav, N.; Khurana, S.M.P. Vaccines: Present Status and Applications. In Animal Biotechnology; Elsevier:
Amsterdam, The Netherlands, 2020; pp. 523–542.
21. Cunningham, A.L.; Garçon, N.; Leo, O.; Friedland, L.R.; Strugnell, R.; Laupèze, B.; Doherty, M.; Stern, P. Vaccine Development:
From Concept to Early Clinical Testing. Vaccine 2016, 34, 6655–6664.
22. Negahdaripour, M.; Vakili, B.; Nezafat, N. Exosome-Based Vaccines and Their Position in next Generation Vaccines. Int.
Immunopharmacol. 2022, 113, 109265.
23. Kallerup, R.S.; Foged, C. Classification of Vaccines. In Subunit Vaccine Delivery; Springer: New York, NY, USA, 2014; pp. 15–29.
24. Vartak, A.; Sucheck, S.J. Recent Advances in Subunit Vaccine Carriers. Vaccines 2016, 4, 12.
25. Rahman, M.M.; Masum, M.H.U.; Talukder, A.; Akter, R. An In Silico Reverse Vaccinology Approach to Design a Novel
Multiepitope Peptide Vaccine for Non-Small Cell Lung Cancers. Inform. Med. Unlocked 2023, 37, 101169.
26. Zhang, L. Multi-Epitope Vaccines: A Promising Strategy against Tumors and Viral Infections. Cell. Mol. Immunol. 2018, 15, 182–
27. Moscicki, A.-B. HPV Vaccines: Today and in the Future. J. Adolesc. Health 2008, 43, S26–S40.
28. Pattyn, J.; Hendrickx, G.; Vorsters, A.; Van Damme, P. Hepatitis B Vaccines. J. Infect. Dis. 2021, 224, S343–S351.
29. Cheever, M.A.; Higano, C.S. PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer
Vaccine. Clin. Cancer Res. 2011, 17, 3520–3526.
30. Lamm, D.L. Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer. J. Urol. 1985, 134, 40–46.
31. Lee, A. Nadofaragene Firadenovec: First Approval. Drugs 2023, 83, 353–357.
32. Larocca, C.A.; LeBoeuf, N.R.; Silk, A.W.; Kaufman, H.L. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the
Treatment of Melanoma: Best Practices and Future Directions. Am. J. Clin. Dermatol. 2020, 21, 821–832.
33. Rojas, L.A.; Sethna, Z.; Soares, K.C.; Olcese, C.; Pang, N.; Patterson, E.; Lihm, J.; Ceglia, N.; Guasp, P.; Chu, A. Personalized
RNA Neoantigen Vaccines Stimulate T Cells in Pancreatic Cancer. Nature 2023, 618, 144–150.
34. Available online: https://Classic.Clinicaltrials.Gov/Ct2/Show/NCT06007092 (accessed on 16 February 2024).
35. Sinha, D.; Roy, S.; Saha, P.; Chatterjee, N.; Bishayee, A. Trends in Research on Exosomes in Cancer Progression and Anticancer
Therapy. Cancers 2021, 13, 326.
36. Crescitelli, R.; Lässer, C.; Lötvall, J. Isolation and Characterization of Extracellular Vesicle Subpopulations from Tissues. Nat.
Protoc. 2021, 16, 1548–1580.
37. Doyle, L.M.; Wang, M.Z. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome
Isolation and Analysis. Cells 2019, 8, 727.
38. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.;
Atkin-Smith, G.K. Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the
International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines. J. Extracell. Vesicles 2018, 7, 1535750.
39. Andreu, Z.; Yáñez-Mó, M. Tetraspanins in Extracellular Vesicle Formation and Function. Front. Immunol. 2014, 5, 442.
40. Panwar, D.; Shrivastava, D.; Bhawal, S.; Gupta, L.K.; Kumar, N.S.S.; Chintagunta, A.D. Detection of Exosomes in Various
Biological Fluids Utilizing Specific Epitopes and Directed Multiple Antigenic Peptide Antibodies. Rev. Anal. Chem. 2023, 42,
41. Xie, Q.-H.; Zheng, J.-Q.; Ding, J.-Y.; Wu, Y.-F.; Liu, L.; Yu, Z.-L.; Chen, G. Exosome-Mediated Immunosuppression in Tumor
Microenvironments. Cells 2022, 11, 1946.
42. Joseph, J.; Rahmani, B.; Cole, Y.; Puttagunta, N.; Lin, E.; Khan, Z.K.; Jain, P. Can Soluble Immune Checkpoint Molecules on
Exosomes Mediate Inflammation? J. Neuroimmune Pharmacol. 2021, 17, 381–397.
43. Hussain, M.W.A.; Jahangir, S.; Ghosh, B.; Yesmin, F.; Anis, A.; Satil, S.N.; Anwar, F.; Rashid, M.H. Exosomes for Regulation of
Immune Responses and Immunotherapy. J. Nanotheranostics 2022, 3, 55–85.
44. Xie, J.; Zheng, Z.; Deng, X.; Tang, H.; Peng, C.; Zou, Y. Recent Advances in Exosome-Based Immunotherapy Applied to Cancer.
Front. Immunol. 2023, 14, 1296857.
45. Skotland, T.; Sandvig, K.; Llorente, A. Lipids in Exosomes: Current Knowledge and the Way Forward. Prog. Lipid. Res. 2017, 66,
46. Regimbeau, M.; Abrey, J.; Vautrot, V.; Causse, S.; Gobbo, J.; Garrido, C. Heat Shock Proteins and Exosomes in Cancer
Theranostics. Semin. Cancer Biol. 2022, 86, 46–57.
47. Colombo, M.; Raposo, G.; Théry, C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular
Vesicles. Annu. Rev. Cell Dev. Biol. 2014, 30, 255–289.
48. Liu, S.-L.; Sun, P.; Li, Y.; Liu, S.-S.; Lu, Y. Exosomes as Critical Mediators of Cell-to-Cell Communication in Cancer Pathogenesis
and Their Potential Clinical Application. Transl. Cancer Res. 2019, 8, 298.
49. Urbanelli, L.; Magini, A.; Buratta, S.; Brozzi, A.; Sagini, K.; Polchi, A.; Tancini, B.; Emiliani, C. Signaling Pathways in Exosomes
Biogenesis, Secretion and Fate. Genes 2013, 4, 152–170.
50. Familtseva, A.; Jeremic, N.; Tyagi, S.C. Exosomes: Cell-Created Drug Delivery Systems. Mol. Cell. Biochem. 2019, 459, 1–6.
51. Hosseini, M.; Khatamianfar, S.; Mahdi Hassanian, S.; Nedaeinia, R.; Shafiee, M.; Maftouh, M.; Ghayour-Mobarhan, M.;
ShahidSales, S.; Avan, A. Exosome-Encapsulated MicroRNAs as Potential Circulating Biomarkers in Colon Cancer. Curr. Pharm.
Des. 2017, 23, 1705–1709.
52. Ferguson, S.W.; Nguyen, J. Exosomes as Therapeutics: The Implications of Molecular Composition and Exosomal Heterogeneity.
J. Control. Release 2016, 228, 179–190.
53. Zhang, Y.; Li, J.; Gao, W.; Xie, N. Exosomes as Anticancer Drug Delivery Vehicles: Prospects and Challenges. Front. Biosci.‐
Landmark 2022, 27, 293.
54. Felder, S.; Miller, K.; Moehren, G.; Ullrich, A.; Schlessinger, J.; Hopkins, C.R. Kinase Activity Controls the Sorting of the
Epidermal Growth Factor Receptor within the Multivesicular Body. Cell 1990, 61, 623–634.
55. Futter, C.E.; Felder, S.; Schlessinger, J.; Ullrich, A.; Hopkins, C.R. Annexin I Is Phosphorylated in the Multivesicular Body during
the Processing of the Epidermal Growth Factor Receptor. J. Cell Biol. 1993, 120, 77–83.
56. Krylova, S.V.; Feng, D. The Machinery of Exosomes: Biogenesis, Release, and Uptake. Int. J. Mol. Sci. 2023, 24, 1337.
57. Tenchov, R.; Sasso, J.M.; Wang, X.; Liaw, W.-S.; Chen, C.-A.; Zhou, Q.A. Exosomes—Nature’s Lipid Nanoparticles, a Rising Star
in Drug Delivery and Diagnostics. ACS Nano 2022, 16, 17802–17846.
58. Van Deurs, B.; Holm, P.K.; Kayser, L.; Sandvig, K.; Hansen, S.H. Multivesicular Bodies in HEp-2 Cells Are Maturing Endosomes.
Eur. J. Cell Biol. 1993, 61, 208–224.
59. Gruenberg, J.; Maxfield, F.R. Membrane Transport in the Endocytic Pathway. Curr. Opin. Cell Biol. 1995, 7, 552–563.
60. Frydrychowicz, M.; Kolecka-Bednarczyk, A.; Madejczyk, M.; Yasar, S.; Dworacki, G. Exosomes–Structure, Biogenesis and
Biological Role in Non-small-cell Lung Cancer. Scand. J. Immunol. 2015, 81, 2–10.
61. Gruenberg, J. Life in the Lumen: The Multivesicular Endosome. Traffic 2020, 21, 76–93.
62. Aheget, H.; Mazini, L.; Martin, F.; Belqat, B.; Marchal, J.A.; Benabdellah, K. Exosomes: Their Role in Pathogenesis, Diagnosis
and Treatment of Diseases. Cancers 2020, 13, 84.
63. Hirsch, J.G.; Fedorko, M.E.; Cohn, Z.A. Vesicle Fusion and Formation at the Surface of Pinocytic Vacuoles in Macrophages. J.
Cell Biol. 1968, 38, 629.
64. Pan, B.-T.; Teng, K.; Wu, C.; Adam, M.; Johnstone, R.M. Electron Microscopic Evidence for Externalization of the Transferrin
Receptor in Vesicular Form in Sheep Reticulocytes. J. Cell Biol. 1985, 101, 942–948.
65. Vidal, M.; Mangeat, P.; Hoekstra, D. Aggregation Reroutes Molecules from a Recycling to a Vesicle-Mediated Secretion Pathway
during Reticulocyte Maturation. J. Cell Sci. 1997, 110, 1867–1877.
66. Avgoulas, D.I.; Tasioulis, K.S.; Papi, R.M.; Pantazaki, A.A. Therapeutic and Diagnostic Potential of Exosomes as Drug Delivery
Systems in Brain Cancer. Pharmaceutics 2023, 15, 1439.
67. Liu, Q.; Li, S.; Dupuy, A.; le Mai, H.; Sailliet, N.; Logé, C.; Robert, J.-M.H.; Brouard, S. Exosomes as New Biomarkers and Drug
Delivery Tools for the Prevention and Treatment of Various Diseases: Current Perspectives. Int. J. Mol. Sci. 2021, 22, 7763.
68. Mosquera-Heredia, M.I.; Morales, L.C.; Vidal, O.M.; Barcelo, E.; Silvera-Redondo, C.; Vélez, J.I.; Garavito-Galofre, P. Exosomes:
Potential Disease Biomarkers and New Therapeutic Targets. Biomedicines 2021, 9, 1061.
69. Akhtar, M.; Haider, A.; Rashid, S.; Al-Nabet, A.D.M.H. Paget’s “Seed and Soil” Theory of Cancer Metastasis: An Idea Whose
Time Has Come. Adv. Anat. Pathol. 2019, 26, 69–74.
70. Chen, H.; Chengalvala, V.; Hu, H.; Sun, D. Tumor-Derived Exosomes: Nanovesicles Made by Cancer Cells to Promote Cancer
Metastasis. Acta Pharm. Sin. B 2021, 11, 2136–2149.
71. Rajput, A.; Varshney, A.; Bajaj, R.; Pokharkar, V. Exosomes as New Generation Vehicles for Drug Delivery: Biomedical
Applications and Future Perspectives. Molecules 2022, 27, 7289.
72. Zitvogel, L.; Regnault, A.; Lozier, A.; Wolfers, J.; Flament, C.; Tenza, D.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S.
Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell Derived Exosomes. Nat. Med. 1998,
73. Essola, J.M.; Zhang, M.; Yang, H.; Li, F.; Xia, B.; Mavoungou, J.F.; Hussain, A.; Huang, Y. Exosome Regulation of Immune
Response Mechanism: Pros and Cons in Immunotherapy. Bioact. Mater. 2024, 32, 124–146.
74. Muller, L.; Mitsuhashi, M.; Simms, P.; Gooding, W.E.; Whiteside, T.L. Tumor-Derived Exosomes Regulate Expression of
Immune Function-Related Genes in Human T Cell Subsets. Sci. Rep. 2016, 6, 20254.
75. Naseri, M.; Bozorgmehr, M.; Zöller, M.; Ranaei Pirmardan, E.; Madjd, Z. Tumor-Derived Exosomes: The next Generation of
Promising Cell-Free Vaccines in Cancer Immunotherapy. Oncoimmunology 2020, 9, 1779991.
76. Peate, I. The Immune System. Br. J. Healthc. Assist. 2021, 15, 492–497.
77. Riera Romo, M.; Pérez-Martínez, D.; Castillo Ferrer, C. Innate Immunity in Vertebrates: An Overview. Immunology 2016, 148,
78. Stewart, J.; Weir, D.M. Innate and Acquired Immunity. In Medical Microbiology; Greenwood, D., Ed.; Churchill Livingstone: New
York, NY, USA, 2012; pp. 109–135.
79. Mukherjee, J.; Das, P.K.; Banerjee, D.; Mukherjee, A. Immune System. In Textbook of Veterinary Physiology; Springer: Singapore,
80. Vickers, P.S. The Immune System. In Fundamentals of Anatomy and Physiology for Student Nurses, 2nd ed.; John Wiley & Sons Ltd.:
Chichester, UK, 2017, 557–594.
81. Sá-Nunes, A. Overview of Immune Responses. In Essential Aspects of Immunometabolism in Health and Disease; Springer: Cham,
Switzerland, 2022; pp. 1–11.
82. LeBien, T.W.; Tedder, T.F. B Lymphocytes: How They Develop and Function. Blood J. Am. Soc. Hematol. 2008, 112, 1570–1580.
83. Cano, R.L.E.; Lopera, H.D.E. Introduction to T and B Lymphocytes. In Autoimmunity: From Bench to Bedside [Internet]; El Rosario
University Press: Bogotá, Colombia, 2013.
84. Thakur, A.; Parra, D.C.; Motallebnejad, P.; Brocchi, M.; Chen, H.J. Exosomes: Small Vesicles with Big Roles in Cancer, Vaccine
Development, and Therapeutics. Bioact. Mater. 2022, 10, 281–294.
85. Ismail, N.; Wang, Y.; Dakhlallah, D.; Moldovan, L.; Agarwal, K.; Batte, K.; Shah, P.; Wisler, J.; Eubank, T.D.; Tridandapani, S.
Macrophage Microvesicles Induce Macrophage Differentiation and MiR-223 Transfer. Blood J. Am. Soc. Hematol. 2013, 121, 984–
86. Eldh, M.; Ekström, K.; Valadi, H.; Sjöstrand, M.; Olsson, B.; Jernås, M.; Lötvall, J. Exosomes Communicate Protective Messages
during Oxidative Stress; Possible Role of Exosomal Shuttle RNA. PLoS ONE 2010, 5, e15353.
87. Jung, I.; Shin, S.; Baek, M.-C.; Yea, K. Modification of Immune Cell-Derived Exosomes for Enhanced Cancer Immunotherapy:
Current Advances and Therapeutic Applications. Exp. Mol. Med. 2024, 56, 19–31.
88. Najafi, S.; Majidpoor, J.; Mortezaee, K. Extracellular Vesicle–Based Drug Delivery in Cancer Immunotherapy. Drug Deliv. Transl.
Res. 2023, 13, 2790–2806.
89. Wang, Z.; Qin, F.; Chen, J. Exosomes: A Promising Avenue for Cancer Diagnosis Beyond Treatment. Front. Cell Dev. Biol. 2024,
90. Harvey, B.T.; Fu, X.; Li, L.; Neupane, K.R.; Anand, N.; Kolesar, J.M.; Richards, C.I. Dendritic Cell Membrane-Derived
Nanovesicles for Targeted T Cell Activation. ACS Omega 2022, 7, 46222–46233.
91. Matsuzaka, Y.; Yashiro, R. Immune Modulation Using Extracellular Vesicles Encapsulated with MicroRNAs as Novel Drug
Delivery Systems. Int. J. Mol. Sci. 2022, 23, 5658.
92. Muntasell, A.; Berger, A.C.; Roche, P.A. T Cell-induced Secretion of MHC Class II–Peptide Complexes on B Cell Exosomes.
EMBO J. 2007, 26, 4263–4272.
93. Wang, Y.; Zhao, M.; Liu, S.; Guo, J.; Lu, Y.; Cheng, J.; Liu, J. Macrophage-Derived Extracellular Vesicles: Diverse Mediators of
Pathology and Therapeutics in Multiple Diseases. Cell Death Dis. 2020, 11, 924.
94. Cheng, L.; Wang, Y.; Huang, L. Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a proInflammatory Microenvironment in the Lymph Node. Mol. Ther. 2017, 25, 1665–1675.
95. Wang, P.; Wang, H.; Huang, Q.; Peng, C.; Yao, L.; Chen, H.; Qiu, Z.; Wu, Y.; Wang, L.; Chen, W. Exosomes from M1-Polarized
Macrophages Enhance Paclitaxel Antitumor Activity by Activating Macrophages-Mediated Inflammation. Theranostics 2019, 9,
96. Zhang, H.; Wang, S.; Sun, M.; Cui, Y.; Xing, J.; Teng, L.; Xi, Z.; Yang, Z. Exosomes as Smart Drug Delivery Vehicles for Cancer
Immunotherapy. Front. Immunol. 2023, 13, 1093607.
97. Afzal, O.; Altamimi, A.S.A.; Nadeem, M.S.; Alzarea, S.I.; Almalki, W.H.; Tariq, A.; Mubeen, B.; Murtaza, B.N.; Iftikhar, S.; Riaz,
N. Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomaterials 2022, 12, 4494.
98. Nam, G.; Choi, Y.; Kim, G.B.; Kim, S.; Kim, S.A.; Kim, I. Emerging Prospects of Exosomes for Cancer Treatment: From
Conventional Therapy to Immunotherapy. Adv. Mater. 2020, 32, 2002440.
99. Ji, P.; Yang, Z.; Li, H.; Wei, M.; Yang, G.; Xing, H.; Li, Q. Smart Exosomes with Lymph Node Homing and Immune-Amplifying
Capacities for Enhanced Immunotherapy of Metastatic Breast Cancer. Mol. Ther.‐Nucleic Acids 2021, 26, 987–996.
100. Gupta, M.; Wahi, A.; Sharma, P.; Nagpal, R.; Raina, N.; Kaurav, M.; Bhattacharya, J.; Rodrigues Oliveira, S.M.; Dolma, K.G.;
Paul, A.K. Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects. Vaccines 2022, 10, 2011.
101. Cuzzubbo, S.; Mangsbo, S.; Nagarajan, D.; Habra, K.; Pockley, A.G.; McArdle, S.E.B. Cancer Vaccines: Adjuvant Potency,
Importance of Age, Lifestyle, and Treatments. Front. Immunol. 2021, 11, 615240.
102. Dutta, A. Exosomes-Based Cell-Free Cancer Therapy: A Novel Strategy for Targeted Therapy. Immunol. Med. 2021, 44, 116–123.
103. Castillo-Peña, A.; Molina-Pinelo, S. Landscape of Tumor and Immune System Cells-Derived Exosomes in Lung Cancer:
Mediators of Antitumor Immunity Regulation. Front. Immunol. 2023, 14, 1279495.
104. Raniszewska, A.; Kwiecień, I.; Rutkowska, E.; Rzepecki, P.; Domagała-Kulawik, J. Lung Cancer Stem Cells—Origin, Diagnostic
Techniques and Perspective for Therapies. Cancers 2021, 13, 2996.
105. Yaddanapudi, K.; Mitchell, R.A.; Putty, K.; Willer, S.; Sharma, R.K.; Yan, J.; Bodduluri, H.; Eaton, J.W. Vaccination with
Embryonic Stem Cells Protects against Lung Cancer: Is a Broad-Spectrum Prophylactic Vaccine against Cancer Possible? PLoS
ONE 2012, 7, e42289.
106. Meng, S.; Whitt, A.G.; Stamp, B.F.; Eaton, J.W.; Li, C.; Yaddanapudi, K. Exosome-Based Cancer Vaccine for Prevention of Lung
Cancer. Stem Cell Investig. 2023, 10, 2.
107. Burke, E.E.; Kodumudi, K.; Ramamoorthi, G.; Czerniecki, B.J. Vaccine Therapies for Breast Cancer. Surg. Oncol. Clin. 2019, 28,
108. Li, R.; Chibbar, R.; Xiang, J. Novel EXO-T Vaccine Using Polyclonal CD4+ T Cells Armed with HER2-Specific Exosomes for
HER2-Positive Breast Cancer. OncoTargets Ther. 2018, 11, 7089–7093.
109. Barok, M.; Puhka, M.; Vereb, G.; Szollosi, J.; Isola, J.; Joensuu, H. Cancer-Derived Exosomes from HER2-Positive Cancer Cells
Carry Trastuzumab-Emtansine into Cancer Cells Leading to Growth Inhibition and Caspase Activation. BMC Cancer 2018, 18,
110. Wang, L.; Xie, Y.; Ahmed, K.A.; Ahmed, S.; Sami, A.; Chibbar, R.; Xu, Q.; Kane, S.E.; Hao, S.; Mulligan, S.J. Exosomal PMHC-I
Complex Targets T Cell-Based Vaccine to Directly Stimulate CTL Responses Leading to Antitumor Immunity in Transgenic
FVBneuN and HLA-A2/HER2 Mice and Eradicating Trastuzumab-Resistant Tumor in Athymic Nude Mice. Breast Cancer Res.
Treat. 2013, 140, 273–284.
111. Xie, Y.; Wu, J.; Xu, A.; Ahmeqd, S.; Sami, A.; Chibbar, R.; Freywald, A.; Zheng, C.; Xiang, J. Heterologous Human/Rat HER2-
Specific Exosome-Targeted T Cell Vaccine Stimulates Potent Humoral and CTL Responses Leading to Enhanced Circumvention
of HER2 Tolerance in Double Transgenic HLA-A2/HER2 Mice. Vaccine 2018, 36, 1414–1422.
112. Huang, L.; Rong, Y.; Tang, X.; Yi, K.; Qi, P.; Hou, J.; Liu, W.; He, Y.; Gao, X.; Yuan, C. Engineered Exosomes as an in Situ DCPrimed Vaccine to Boost Antitumor Immunity in Breast Cancer. Mol. Cancer 2022, 21, 45.
113. Lambert, A.; Schwarz, L.; Borbath, I.; Henry, A.; Van Laethem, J.-L.; Malka, D.; Ducreux, M.; Conroy, T. An Update on Treatment
Options for Pancreatic Adenocarcinoma. Ther. Adv. Med. Oncol. 2019, 11, 1758835919875568.
114. Xiao, L.; Erb, U.; Zhao, K.; Hackert, T.; Zöller, M. Efficacy of Vaccination with Tumor-Exosome Loaded Dendritic Cells
Combined with Cytotoxic Drug Treatment in Pancreatic Cancer. Oncoimmunology 2017, 6, e1319044.
115. Richards, K.E.; Zeleniak, A.E.; Fishel, M.L.; Wu, J.; Littlepage, L.E.; Hill, R. Cancer-Associated Fibroblast Exosomes Regulate
Survival and Proliferation of Pancreatic Cancer Cells. Oncogene 2017, 36, 1770–1778.
116. Batista, I.A.; Melo, S.A. Exosomes and the Future of Immunotherapy in Pancreatic Cancer. Int. J. Mol. Sci. 2019, 20, 567.
117. Hoshino, A.; Costa-Silva, B.; Shen, T.-L.; Rodrigues, G.; Hashimoto, A.; Tesic Mark, M.; Molina, H.; Kohsaka, S.; Di Giannatale,
A.; Ceder, S. Tumour Exosome Integrins Determine Organotropic Metastasis. Nature 2015, 527, 329–335.
118. Su, M.-J.; Aldawsari, H.; Amiji, M. Pancreatic Cancer Cell Exosome-Mediated Macrophage Reprogramming and the Role of
MicroRNAs 155 and 125b2 Transfection Using Nanoparticle Delivery Systems. Sci. Rep. 2016, 6, 30110.
119. Liu, Y.; Li, X.; Zhang, T.; Liu, G. The Roles of Exosomes in Ovarian Cancer Chemo-Resistance. J. Cancer 2023, 14, 2128.
120. Li, X.; Wang, X. The Emerging Roles and Therapeutic Potential of Exosomes in Epithelial Ovarian Cancer. Mol. Cancer 2017, 16,
121. Reza, A.M.M.T.; Choi, Y.-J.; Yasuda, H.; Kim, J.-H. Human Adipose Mesenchymal Stem Cell-Derived Exosomal-MiRNAs Are
Critical Factors for Inducing Anti-Proliferation Signalling to A2780 and SKOV-3 Ovarian Cancer Cells. Sci. Rep. 2016, 6, 38498.
122. Li, Q.-L.; Bu, N.; Yu, Y.-C.; Hua, W.; Xin, X.-Y. Exvivo Experiments of Human Ovarian Cancer Ascites-Derived Exosomes
Presented by Dendritic Cells Derived from Umbilical Cord Blood for Immunotherapy Treatment. Clin. Med. Oncol. 2008, 2, 461–
123. Odunsi, K. Immunotherapy in Ovarian Cancer. Ann. Oncol. 2017, 28, viii1–viii7.
124. Fu, S.; Wang, Y.; Xia, X.; Zheng, J.C. Exosome Engineering: Current Progress in Cargo Loading and Targeted Delivery.
NanoImpact 2020, 20, 100261
Vaccines, 2024 May; 12: 519-535.
Export to BibTeX Export to EndNote
Paper type: Review Journal Article
Impact factor: 7.8, 5-year impact factor: 7.4
Url: https://doi.org/10.3390/vaccines12050519
Keywords: Exosomes, Cancer Vaccines: Immune System
Affiliations:
*** IBB - CNR ***
References:
1. Available online: https://Gco.Iarc.Fr/Tomorrow/En/Dataviz/Isotype (accessed on 16 February 2024).
2. De Rosa, V.; Iommelli, F.; Monti, M.; Fonti, R.; Votta, G.; Stoppelli, M.P.; Del Vecchio, S. Reversal of Warburg Effect and
Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung
Cancer. Clin. Cancer Res. 2015, 21, 5110–5120.
3. De Rosa, V.; Monti, M.; Terlizzi, C.; Fonti, R.; Del Vecchio, S.; Iommelli, F. Coordinate Modulation of Glycolytic Enzymes and
OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells. Int. J. Mol. Sci. 2019, 20, 3134.
4. Iommelli, F.; De Rosa, V.; Gargiulo, S.; Panico, M.; Monti, M.; Greco, A.; Gramanzini, M.; Ortosecco, G.; Fonti, R.; Brunetti, A.
Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using
3′-Deoxy-3′-[18F]-Fluorothymidine Positron Emission Tomography. Clin. Cancer Res. 2014, 20, 4806–4815.
5. Terlizzi, C.; De Rosa, V.; Iommelli, F.; Pezone, A.; Altobelli, G.G.; Maddalena, M.; Dimitrov, J.; De Rosa, C.; Della Corte, C.M.;
Avvedimento, V.E. ATM Inhibition Blocks Glucose Metabolism and Amplifies the Sensitivity of Resistant Lung Cancer Cell
Lines to Oncogene Driver Inhibitors. Cancer Metab. 2023, 11, 20.
6. De Rosa, V.; Iommelli, F.; Terlizzi, C.; Leggiero, E.; Camerlingo, R.; Altobelli, G.G.; Fonti, R.; Pastore, L.; Del Vecchio, S. NonCanonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER–
Mitochondria Interface in Oncogene-Driven NSCLC. Cancers 2021, 13, 4133.
7. Iommelli, F.; De Rosa, V.; Terlizzi, C.; Fonti, R.; Camerlingo, R.; Stoppelli, M.P.; Stewart, C.A.; Byers, L.A.; Piwnica-Worms, D.;
Del Vecchio, S. A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of
Resistance to Tyrosine Kinase Inhibitors. Cancers 2021, 13, 2022.
8. Iommelli, F.; De Rosa, V.; Terlizzi, C.; Monti, M.; Panico, M.; Fonti, R.; Del Vecchio, S. Inositol Trisphosphate Receptor Type 3-
Mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non–Small Cell Lung Cancer Detected by 18FFluorothymidine. Clin. Cancer Res. 2018, 24, 3126–3136.
9. Mulliri, S.; Laaksonen, A.; Spanu, P.; Farris, R.; Farci, M.; Mingoia, F.; Roviello, G.N.; Mocci, F. Spectroscopic and in Silico
Studies on the Interaction of Substituted Pyrazolo [1, 2-a] Benzo [1, 2, 3, 4] Tetrazine-3-One Derivatives with c-Myc G4-DNA.
Int. J. Mol. Sci. 2021, 22, 6028.
10. Fik-Jaskółka, M.A.; Mkrtchyan, A.F.; Saghyan, A.S.; Palumbo, R.; Belter, A.; Hayriyan, L.A.; Simonyan, H.; Roviello, V.; Roviello,
G.N. Spectroscopic and SEM Evidences for G4-DNA Binding by a Synthetic Alkyne-Containing Amino Acid with Anticancer
Activity. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2020, 229, 117884.
11. Greco, F.; Musumeci, D.; Borbone, N.; Falanga, A.P.; D’Errico, S.; Terracciano, M.; Piccialli, I.; Roviello, G.N.; Oliviero, G.
Exploring the Parallel G-Quadruplex Nucleic Acid World: A Spectroscopic and Computational Investigation on the Binding of
the c-Myc Oncogene Nhe III1 Region by the Phytochemical Polydatin. Molecules 2022, 27, 2997.
12. Marzano, M.; Falanga, A.P.; Marasco, D.; Borbone, N.; D’Errico, S.; Piccialli, G.; Roviello, G.N.; Oliviero, G. Evaluation of an
Analogue of the Marine ε-PLL Peptide as a Ligand of G-Quadruplex DNA Structures. Mar. Drugs 2020, 18, 49.
13. Falanga, A.P.; Terracciano, M.; Oliviero, G.; Roviello, G.N.; Borbone, N. Exploring the Relationship between G-Quadruplex
Nucleic Acids and Plants: From Plant G-Quadruplex Function to Phytochemical G4 Ligands with Pharmaceutic Potential.
Pharmaceutics 2022, 14, 2377.
14. Butterfield, L.H. Cancer Vaccines. BMJ 2015, 350, h988.
15. Tagliamonte, M.; Petrizzo, A.; Tornesello, M.L.; Buonaguro, F.M.; Buonaguro, L. Antigen-Specific Vaccines for Cancer
Treatment. Hum. Vaccines Immunother. 2014, 10, 3332–3346.
Vaccines 2024, 12, 519 14 of 17
16. Zhao, Y.; Baldin, A.V.; Isayev, O.; Werner, J.; Zamyatnin, A.A., Jr.; Bazhin, A. V Cancer Vaccines: Antigen Selection Strategy.
Vaccines 2021, 9, 85.
17. Lyu, C.; Sun, H.; Sun, Z.; Liu, Y.; Wang, Q. Roles of Exosomes in Immunotherapy for Solid Cancers. Cell Death Dis. 2024, 15, 106.
18. Plotkin, S.L.; Plotkin, S.A. A Short History of Vaccination. Vaccines 2012, 4, 1–13.
19. Depelsenaire, A.C.I.; Kendall, M.A.F.; Young, P.R.; Muller, D.A. Introduction to Vaccines and Vaccination. In Micro and
Nanotechnology in Vaccine Development; Elsevier: Amsterdam, The Netherlands, 2017; pp. 47–62.
20. Yadav, D.K.; Yadav, N.; Khurana, S.M.P. Vaccines: Present Status and Applications. In Animal Biotechnology; Elsevier:
Amsterdam, The Netherlands, 2020; pp. 523–542.
21. Cunningham, A.L.; Garçon, N.; Leo, O.; Friedland, L.R.; Strugnell, R.; Laupèze, B.; Doherty, M.; Stern, P. Vaccine Development:
From Concept to Early Clinical Testing. Vaccine 2016, 34, 6655–6664.
22. Negahdaripour, M.; Vakili, B.; Nezafat, N. Exosome-Based Vaccines and Their Position in next Generation Vaccines. Int.
Immunopharmacol. 2022, 113, 109265.
23. Kallerup, R.S.; Foged, C. Classification of Vaccines. In Subunit Vaccine Delivery; Springer: New York, NY, USA, 2014; pp. 15–29.
24. Vartak, A.; Sucheck, S.J. Recent Advances in Subunit Vaccine Carriers. Vaccines 2016, 4, 12.
25. Rahman, M.M.; Masum, M.H.U.; Talukder, A.; Akter, R. An In Silico Reverse Vaccinology Approach to Design a Novel
Multiepitope Peptide Vaccine for Non-Small Cell Lung Cancers. Inform. Med. Unlocked 2023, 37, 101169.
26. Zhang, L. Multi-Epitope Vaccines: A Promising Strategy against Tumors and Viral Infections. Cell. Mol. Immunol. 2018, 15, 182–
27. Moscicki, A.-B. HPV Vaccines: Today and in the Future. J. Adolesc. Health 2008, 43, S26–S40.
28. Pattyn, J.; Hendrickx, G.; Vorsters, A.; Van Damme, P. Hepatitis B Vaccines. J. Infect. Dis. 2021, 224, S343–S351.
29. Cheever, M.A.; Higano, C.S. PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer
Vaccine. Clin. Cancer Res. 2011, 17, 3520–3526.
30. Lamm, D.L. Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer. J. Urol. 1985, 134, 40–46.
31. Lee, A. Nadofaragene Firadenovec: First Approval. Drugs 2023, 83, 353–357.
32. Larocca, C.A.; LeBoeuf, N.R.; Silk, A.W.; Kaufman, H.L. An Update on the Role of Talimogene Laherparepvec (T-VEC) in the
Treatment of Melanoma: Best Practices and Future Directions. Am. J. Clin. Dermatol. 2020, 21, 821–832.
33. Rojas, L.A.; Sethna, Z.; Soares, K.C.; Olcese, C.; Pang, N.; Patterson, E.; Lihm, J.; Ceglia, N.; Guasp, P.; Chu, A. Personalized
RNA Neoantigen Vaccines Stimulate T Cells in Pancreatic Cancer. Nature 2023, 618, 144–150.
34. Available online: https://Classic.Clinicaltrials.Gov/Ct2/Show/NCT06007092 (accessed on 16 February 2024).
35. Sinha, D.; Roy, S.; Saha, P.; Chatterjee, N.; Bishayee, A. Trends in Research on Exosomes in Cancer Progression and Anticancer
Therapy. Cancers 2021, 13, 326.
36. Crescitelli, R.; Lässer, C.; Lötvall, J. Isolation and Characterization of Extracellular Vesicle Subpopulations from Tissues. Nat.
Protoc. 2021, 16, 1548–1580.
37. Doyle, L.M.; Wang, M.Z. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome
Isolation and Analysis. Cells 2019, 8, 727.
38. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.;
Atkin-Smith, G.K. Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the
International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines. J. Extracell. Vesicles 2018, 7, 1535750.
39. Andreu, Z.; Yáñez-Mó, M. Tetraspanins in Extracellular Vesicle Formation and Function. Front. Immunol. 2014, 5, 442.
40. Panwar, D.; Shrivastava, D.; Bhawal, S.; Gupta, L.K.; Kumar, N.S.S.; Chintagunta, A.D. Detection of Exosomes in Various
Biological Fluids Utilizing Specific Epitopes and Directed Multiple Antigenic Peptide Antibodies. Rev. Anal. Chem. 2023, 42,
41. Xie, Q.-H.; Zheng, J.-Q.; Ding, J.-Y.; Wu, Y.-F.; Liu, L.; Yu, Z.-L.; Chen, G. Exosome-Mediated Immunosuppression in Tumor
Microenvironments. Cells 2022, 11, 1946.
42. Joseph, J.; Rahmani, B.; Cole, Y.; Puttagunta, N.; Lin, E.; Khan, Z.K.; Jain, P. Can Soluble Immune Checkpoint Molecules on
Exosomes Mediate Inflammation? J. Neuroimmune Pharmacol. 2021, 17, 381–397.
43. Hussain, M.W.A.; Jahangir, S.; Ghosh, B.; Yesmin, F.; Anis, A.; Satil, S.N.; Anwar, F.; Rashid, M.H. Exosomes for Regulation of
Immune Responses and Immunotherapy. J. Nanotheranostics 2022, 3, 55–85.
44. Xie, J.; Zheng, Z.; Deng, X.; Tang, H.; Peng, C.; Zou, Y. Recent Advances in Exosome-Based Immunotherapy Applied to Cancer.
Front. Immunol. 2023, 14, 1296857.
45. Skotland, T.; Sandvig, K.; Llorente, A. Lipids in Exosomes: Current Knowledge and the Way Forward. Prog. Lipid. Res. 2017, 66,
46. Regimbeau, M.; Abrey, J.; Vautrot, V.; Causse, S.; Gobbo, J.; Garrido, C. Heat Shock Proteins and Exosomes in Cancer
Theranostics. Semin. Cancer Biol. 2022, 86, 46–57.
47. Colombo, M.; Raposo, G.; Théry, C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular
Vesicles. Annu. Rev. Cell Dev. Biol. 2014, 30, 255–289.
48. Liu, S.-L.; Sun, P.; Li, Y.; Liu, S.-S.; Lu, Y. Exosomes as Critical Mediators of Cell-to-Cell Communication in Cancer Pathogenesis
and Their Potential Clinical Application. Transl. Cancer Res. 2019, 8, 298.
49. Urbanelli, L.; Magini, A.; Buratta, S.; Brozzi, A.; Sagini, K.; Polchi, A.; Tancini, B.; Emiliani, C. Signaling Pathways in Exosomes
Biogenesis, Secretion and Fate. Genes 2013, 4, 152–170.
50. Familtseva, A.; Jeremic, N.; Tyagi, S.C. Exosomes: Cell-Created Drug Delivery Systems. Mol. Cell. Biochem. 2019, 459, 1–6.
51. Hosseini, M.; Khatamianfar, S.; Mahdi Hassanian, S.; Nedaeinia, R.; Shafiee, M.; Maftouh, M.; Ghayour-Mobarhan, M.;
ShahidSales, S.; Avan, A. Exosome-Encapsulated MicroRNAs as Potential Circulating Biomarkers in Colon Cancer. Curr. Pharm.
Des. 2017, 23, 1705–1709.
52. Ferguson, S.W.; Nguyen, J. Exosomes as Therapeutics: The Implications of Molecular Composition and Exosomal Heterogeneity.
J. Control. Release 2016, 228, 179–190.
53. Zhang, Y.; Li, J.; Gao, W.; Xie, N. Exosomes as Anticancer Drug Delivery Vehicles: Prospects and Challenges. Front. Biosci.‐
Landmark 2022, 27, 293.
54. Felder, S.; Miller, K.; Moehren, G.; Ullrich, A.; Schlessinger, J.; Hopkins, C.R. Kinase Activity Controls the Sorting of the
Epidermal Growth Factor Receptor within the Multivesicular Body. Cell 1990, 61, 623–634.
55. Futter, C.E.; Felder, S.; Schlessinger, J.; Ullrich, A.; Hopkins, C.R. Annexin I Is Phosphorylated in the Multivesicular Body during
the Processing of the Epidermal Growth Factor Receptor. J. Cell Biol. 1993, 120, 77–83.
56. Krylova, S.V.; Feng, D. The Machinery of Exosomes: Biogenesis, Release, and Uptake. Int. J. Mol. Sci. 2023, 24, 1337.
57. Tenchov, R.; Sasso, J.M.; Wang, X.; Liaw, W.-S.; Chen, C.-A.; Zhou, Q.A. Exosomes—Nature’s Lipid Nanoparticles, a Rising Star
in Drug Delivery and Diagnostics. ACS Nano 2022, 16, 17802–17846.
58. Van Deurs, B.; Holm, P.K.; Kayser, L.; Sandvig, K.; Hansen, S.H. Multivesicular Bodies in HEp-2 Cells Are Maturing Endosomes.
Eur. J. Cell Biol. 1993, 61, 208–224.
59. Gruenberg, J.; Maxfield, F.R. Membrane Transport in the Endocytic Pathway. Curr. Opin. Cell Biol. 1995, 7, 552–563.
60. Frydrychowicz, M.; Kolecka-Bednarczyk, A.; Madejczyk, M.; Yasar, S.; Dworacki, G. Exosomes–Structure, Biogenesis and
Biological Role in Non-small-cell Lung Cancer. Scand. J. Immunol. 2015, 81, 2–10.
61. Gruenberg, J. Life in the Lumen: The Multivesicular Endosome. Traffic 2020, 21, 76–93.
62. Aheget, H.; Mazini, L.; Martin, F.; Belqat, B.; Marchal, J.A.; Benabdellah, K. Exosomes: Their Role in Pathogenesis, Diagnosis
and Treatment of Diseases. Cancers 2020, 13, 84.
63. Hirsch, J.G.; Fedorko, M.E.; Cohn, Z.A. Vesicle Fusion and Formation at the Surface of Pinocytic Vacuoles in Macrophages. J.
Cell Biol. 1968, 38, 629.
64. Pan, B.-T.; Teng, K.; Wu, C.; Adam, M.; Johnstone, R.M. Electron Microscopic Evidence for Externalization of the Transferrin
Receptor in Vesicular Form in Sheep Reticulocytes. J. Cell Biol. 1985, 101, 942–948.
65. Vidal, M.; Mangeat, P.; Hoekstra, D. Aggregation Reroutes Molecules from a Recycling to a Vesicle-Mediated Secretion Pathway
during Reticulocyte Maturation. J. Cell Sci. 1997, 110, 1867–1877.
66. Avgoulas, D.I.; Tasioulis, K.S.; Papi, R.M.; Pantazaki, A.A. Therapeutic and Diagnostic Potential of Exosomes as Drug Delivery
Systems in Brain Cancer. Pharmaceutics 2023, 15, 1439.
67. Liu, Q.; Li, S.; Dupuy, A.; le Mai, H.; Sailliet, N.; Logé, C.; Robert, J.-M.H.; Brouard, S. Exosomes as New Biomarkers and Drug
Delivery Tools for the Prevention and Treatment of Various Diseases: Current Perspectives. Int. J. Mol. Sci. 2021, 22, 7763.
68. Mosquera-Heredia, M.I.; Morales, L.C.; Vidal, O.M.; Barcelo, E.; Silvera-Redondo, C.; Vélez, J.I.; Garavito-Galofre, P. Exosomes:
Potential Disease Biomarkers and New Therapeutic Targets. Biomedicines 2021, 9, 1061.
69. Akhtar, M.; Haider, A.; Rashid, S.; Al-Nabet, A.D.M.H. Paget’s “Seed and Soil” Theory of Cancer Metastasis: An Idea Whose
Time Has Come. Adv. Anat. Pathol. 2019, 26, 69–74.
70. Chen, H.; Chengalvala, V.; Hu, H.; Sun, D. Tumor-Derived Exosomes: Nanovesicles Made by Cancer Cells to Promote Cancer
Metastasis. Acta Pharm. Sin. B 2021, 11, 2136–2149.
71. Rajput, A.; Varshney, A.; Bajaj, R.; Pokharkar, V. Exosomes as New Generation Vehicles for Drug Delivery: Biomedical
Applications and Future Perspectives. Molecules 2022, 27, 7289.
72. Zitvogel, L.; Regnault, A.; Lozier, A.; Wolfers, J.; Flament, C.; Tenza, D.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S.
Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell Derived Exosomes. Nat. Med. 1998,
73. Essola, J.M.; Zhang, M.; Yang, H.; Li, F.; Xia, B.; Mavoungou, J.F.; Hussain, A.; Huang, Y. Exosome Regulation of Immune
Response Mechanism: Pros and Cons in Immunotherapy. Bioact. Mater. 2024, 32, 124–146.
74. Muller, L.; Mitsuhashi, M.; Simms, P.; Gooding, W.E.; Whiteside, T.L. Tumor-Derived Exosomes Regulate Expression of
Immune Function-Related Genes in Human T Cell Subsets. Sci. Rep. 2016, 6, 20254.
75. Naseri, M.; Bozorgmehr, M.; Zöller, M.; Ranaei Pirmardan, E.; Madjd, Z. Tumor-Derived Exosomes: The next Generation of
Promising Cell-Free Vaccines in Cancer Immunotherapy. Oncoimmunology 2020, 9, 1779991.
76. Peate, I. The Immune System. Br. J. Healthc. Assist. 2021, 15, 492–497.
77. Riera Romo, M.; Pérez-Martínez, D.; Castillo Ferrer, C. Innate Immunity in Vertebrates: An Overview. Immunology 2016, 148,
78. Stewart, J.; Weir, D.M. Innate and Acquired Immunity. In Medical Microbiology; Greenwood, D., Ed.; Churchill Livingstone: New
York, NY, USA, 2012; pp. 109–135.
79. Mukherjee, J.; Das, P.K.; Banerjee, D.; Mukherjee, A. Immune System. In Textbook of Veterinary Physiology; Springer: Singapore,
80. Vickers, P.S. The Immune System. In Fundamentals of Anatomy and Physiology for Student Nurses, 2nd ed.; John Wiley & Sons Ltd.:
Chichester, UK, 2017, 557–594.
81. Sá-Nunes, A. Overview of Immune Responses. In Essential Aspects of Immunometabolism in Health and Disease; Springer: Cham,
Switzerland, 2022; pp. 1–11.
82. LeBien, T.W.; Tedder, T.F. B Lymphocytes: How They Develop and Function. Blood J. Am. Soc. Hematol. 2008, 112, 1570–1580.
83. Cano, R.L.E.; Lopera, H.D.E. Introduction to T and B Lymphocytes. In Autoimmunity: From Bench to Bedside [Internet]; El Rosario
University Press: Bogotá, Colombia, 2013.
84. Thakur, A.; Parra, D.C.; Motallebnejad, P.; Brocchi, M.; Chen, H.J. Exosomes: Small Vesicles with Big Roles in Cancer, Vaccine
Development, and Therapeutics. Bioact. Mater. 2022, 10, 281–294.
85. Ismail, N.; Wang, Y.; Dakhlallah, D.; Moldovan, L.; Agarwal, K.; Batte, K.; Shah, P.; Wisler, J.; Eubank, T.D.; Tridandapani, S.
Macrophage Microvesicles Induce Macrophage Differentiation and MiR-223 Transfer. Blood J. Am. Soc. Hematol. 2013, 121, 984–
86. Eldh, M.; Ekström, K.; Valadi, H.; Sjöstrand, M.; Olsson, B.; Jernås, M.; Lötvall, J. Exosomes Communicate Protective Messages
during Oxidative Stress; Possible Role of Exosomal Shuttle RNA. PLoS ONE 2010, 5, e15353.
87. Jung, I.; Shin, S.; Baek, M.-C.; Yea, K. Modification of Immune Cell-Derived Exosomes for Enhanced Cancer Immunotherapy:
Current Advances and Therapeutic Applications. Exp. Mol. Med. 2024, 56, 19–31.
88. Najafi, S.; Majidpoor, J.; Mortezaee, K. Extracellular Vesicle–Based Drug Delivery in Cancer Immunotherapy. Drug Deliv. Transl.
Res. 2023, 13, 2790–2806.
89. Wang, Z.; Qin, F.; Chen, J. Exosomes: A Promising Avenue for Cancer Diagnosis Beyond Treatment. Front. Cell Dev. Biol. 2024,
90. Harvey, B.T.; Fu, X.; Li, L.; Neupane, K.R.; Anand, N.; Kolesar, J.M.; Richards, C.I. Dendritic Cell Membrane-Derived
Nanovesicles for Targeted T Cell Activation. ACS Omega 2022, 7, 46222–46233.
91. Matsuzaka, Y.; Yashiro, R. Immune Modulation Using Extracellular Vesicles Encapsulated with MicroRNAs as Novel Drug
Delivery Systems. Int. J. Mol. Sci. 2022, 23, 5658.
92. Muntasell, A.; Berger, A.C.; Roche, P.A. T Cell-induced Secretion of MHC Class II–Peptide Complexes on B Cell Exosomes.
EMBO J. 2007, 26, 4263–4272.
93. Wang, Y.; Zhao, M.; Liu, S.; Guo, J.; Lu, Y.; Cheng, J.; Liu, J. Macrophage-Derived Extracellular Vesicles: Diverse Mediators of
Pathology and Therapeutics in Multiple Diseases. Cell Death Dis. 2020, 11, 924.
94. Cheng, L.; Wang, Y.; Huang, L. Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a proInflammatory Microenvironment in the Lymph Node. Mol. Ther. 2017, 25, 1665–1675.
95. Wang, P.; Wang, H.; Huang, Q.; Peng, C.; Yao, L.; Chen, H.; Qiu, Z.; Wu, Y.; Wang, L.; Chen, W. Exosomes from M1-Polarized
Macrophages Enhance Paclitaxel Antitumor Activity by Activating Macrophages-Mediated Inflammation. Theranostics 2019, 9,
96. Zhang, H.; Wang, S.; Sun, M.; Cui, Y.; Xing, J.; Teng, L.; Xi, Z.; Yang, Z. Exosomes as Smart Drug Delivery Vehicles for Cancer
Immunotherapy. Front. Immunol. 2023, 13, 1093607.
97. Afzal, O.; Altamimi, A.S.A.; Nadeem, M.S.; Alzarea, S.I.; Almalki, W.H.; Tariq, A.; Mubeen, B.; Murtaza, B.N.; Iftikhar, S.; Riaz,
N. Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomaterials 2022, 12, 4494.
98. Nam, G.; Choi, Y.; Kim, G.B.; Kim, S.; Kim, S.A.; Kim, I. Emerging Prospects of Exosomes for Cancer Treatment: From
Conventional Therapy to Immunotherapy. Adv. Mater. 2020, 32, 2002440.
99. Ji, P.; Yang, Z.; Li, H.; Wei, M.; Yang, G.; Xing, H.; Li, Q. Smart Exosomes with Lymph Node Homing and Immune-Amplifying
Capacities for Enhanced Immunotherapy of Metastatic Breast Cancer. Mol. Ther.‐Nucleic Acids 2021, 26, 987–996.
100. Gupta, M.; Wahi, A.; Sharma, P.; Nagpal, R.; Raina, N.; Kaurav, M.; Bhattacharya, J.; Rodrigues Oliveira, S.M.; Dolma, K.G.;
Paul, A.K. Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects. Vaccines 2022, 10, 2011.
101. Cuzzubbo, S.; Mangsbo, S.; Nagarajan, D.; Habra, K.; Pockley, A.G.; McArdle, S.E.B. Cancer Vaccines: Adjuvant Potency,
Importance of Age, Lifestyle, and Treatments. Front. Immunol. 2021, 11, 615240.
102. Dutta, A. Exosomes-Based Cell-Free Cancer Therapy: A Novel Strategy for Targeted Therapy. Immunol. Med. 2021, 44, 116–123.
103. Castillo-Peña, A.; Molina-Pinelo, S. Landscape of Tumor and Immune System Cells-Derived Exosomes in Lung Cancer:
Mediators of Antitumor Immunity Regulation. Front. Immunol. 2023, 14, 1279495.
104. Raniszewska, A.; Kwiecień, I.; Rutkowska, E.; Rzepecki, P.; Domagała-Kulawik, J. Lung Cancer Stem Cells—Origin, Diagnostic
Techniques and Perspective for Therapies. Cancers 2021, 13, 2996.
105. Yaddanapudi, K.; Mitchell, R.A.; Putty, K.; Willer, S.; Sharma, R.K.; Yan, J.; Bodduluri, H.; Eaton, J.W. Vaccination with
Embryonic Stem Cells Protects against Lung Cancer: Is a Broad-Spectrum Prophylactic Vaccine against Cancer Possible? PLoS
ONE 2012, 7, e42289.
106. Meng, S.; Whitt, A.G.; Stamp, B.F.; Eaton, J.W.; Li, C.; Yaddanapudi, K. Exosome-Based Cancer Vaccine for Prevention of Lung
Cancer. Stem Cell Investig. 2023, 10, 2.
107. Burke, E.E.; Kodumudi, K.; Ramamoorthi, G.; Czerniecki, B.J. Vaccine Therapies for Breast Cancer. Surg. Oncol. Clin. 2019, 28,
108. Li, R.; Chibbar, R.; Xiang, J. Novel EXO-T Vaccine Using Polyclonal CD4+ T Cells Armed with HER2-Specific Exosomes for
HER2-Positive Breast Cancer. OncoTargets Ther. 2018, 11, 7089–7093.
109. Barok, M.; Puhka, M.; Vereb, G.; Szollosi, J.; Isola, J.; Joensuu, H. Cancer-Derived Exosomes from HER2-Positive Cancer Cells
Carry Trastuzumab-Emtansine into Cancer Cells Leading to Growth Inhibition and Caspase Activation. BMC Cancer 2018, 18,
110. Wang, L.; Xie, Y.; Ahmed, K.A.; Ahmed, S.; Sami, A.; Chibbar, R.; Xu, Q.; Kane, S.E.; Hao, S.; Mulligan, S.J. Exosomal PMHC-I
Complex Targets T Cell-Based Vaccine to Directly Stimulate CTL Responses Leading to Antitumor Immunity in Transgenic
FVBneuN and HLA-A2/HER2 Mice and Eradicating Trastuzumab-Resistant Tumor in Athymic Nude Mice. Breast Cancer Res.
Treat. 2013, 140, 273–284.
111. Xie, Y.; Wu, J.; Xu, A.; Ahmeqd, S.; Sami, A.; Chibbar, R.; Freywald, A.; Zheng, C.; Xiang, J. Heterologous Human/Rat HER2-
Specific Exosome-Targeted T Cell Vaccine Stimulates Potent Humoral and CTL Responses Leading to Enhanced Circumvention
of HER2 Tolerance in Double Transgenic HLA-A2/HER2 Mice. Vaccine 2018, 36, 1414–1422.
112. Huang, L.; Rong, Y.; Tang, X.; Yi, K.; Qi, P.; Hou, J.; Liu, W.; He, Y.; Gao, X.; Yuan, C. Engineered Exosomes as an in Situ DCPrimed Vaccine to Boost Antitumor Immunity in Breast Cancer. Mol. Cancer 2022, 21, 45.
113. Lambert, A.; Schwarz, L.; Borbath, I.; Henry, A.; Van Laethem, J.-L.; Malka, D.; Ducreux, M.; Conroy, T. An Update on Treatment
Options for Pancreatic Adenocarcinoma. Ther. Adv. Med. Oncol. 2019, 11, 1758835919875568.
114. Xiao, L.; Erb, U.; Zhao, K.; Hackert, T.; Zöller, M. Efficacy of Vaccination with Tumor-Exosome Loaded Dendritic Cells
Combined with Cytotoxic Drug Treatment in Pancreatic Cancer. Oncoimmunology 2017, 6, e1319044.
115. Richards, K.E.; Zeleniak, A.E.; Fishel, M.L.; Wu, J.; Littlepage, L.E.; Hill, R. Cancer-Associated Fibroblast Exosomes Regulate
Survival and Proliferation of Pancreatic Cancer Cells. Oncogene 2017, 36, 1770–1778.
116. Batista, I.A.; Melo, S.A. Exosomes and the Future of Immunotherapy in Pancreatic Cancer. Int. J. Mol. Sci. 2019, 20, 567.
117. Hoshino, A.; Costa-Silva, B.; Shen, T.-L.; Rodrigues, G.; Hashimoto, A.; Tesic Mark, M.; Molina, H.; Kohsaka, S.; Di Giannatale,
A.; Ceder, S. Tumour Exosome Integrins Determine Organotropic Metastasis. Nature 2015, 527, 329–335.
118. Su, M.-J.; Aldawsari, H.; Amiji, M. Pancreatic Cancer Cell Exosome-Mediated Macrophage Reprogramming and the Role of
MicroRNAs 155 and 125b2 Transfection Using Nanoparticle Delivery Systems. Sci. Rep. 2016, 6, 30110.
119. Liu, Y.; Li, X.; Zhang, T.; Liu, G. The Roles of Exosomes in Ovarian Cancer Chemo-Resistance. J. Cancer 2023, 14, 2128.
120. Li, X.; Wang, X. The Emerging Roles and Therapeutic Potential of Exosomes in Epithelial Ovarian Cancer. Mol. Cancer 2017, 16,
121. Reza, A.M.M.T.; Choi, Y.-J.; Yasuda, H.; Kim, J.-H. Human Adipose Mesenchymal Stem Cell-Derived Exosomal-MiRNAs Are
Critical Factors for Inducing Anti-Proliferation Signalling to A2780 and SKOV-3 Ovarian Cancer Cells. Sci. Rep. 2016, 6, 38498.
122. Li, Q.-L.; Bu, N.; Yu, Y.-C.; Hua, W.; Xin, X.-Y. Exvivo Experiments of Human Ovarian Cancer Ascites-Derived Exosomes
Presented by Dendritic Cells Derived from Umbilical Cord Blood for Immunotherapy Treatment. Clin. Med. Oncol. 2008, 2, 461–
123. Odunsi, K. Immunotherapy in Ovarian Cancer. Ann. Oncol. 2017, 28, viii1–viii7.
124. Fu, S.; Wang, Y.; Xia, X.; Zheng, J.C. Exosome Engineering: Current Progress in Cargo Loading and Targeted Delivery.
NanoImpact 2020, 20, 100261
Exosome-like Systems: From Therapies to Vaccination for Cancer Treatment and Prevention—Exploring the State of the Art
Cancer remains one of the main causes of death in the world due to its increasing incidence and treatment difficulties. Although significant progress has been made in this field, innovative approaches are needed to reduce tumor incidence, progression, and spread. In particular, the development of cancer vaccines is currently ongoing as both a preventive and therapeutic strategy. This concept is not new, but few vaccines have been approved in oncology. Antigen-based vaccination emerges as a promising strategy, leveraging specific tumor antigens to activate the immune system response. However, challenges persist in finding suitable delivery systems and antigen preparation methods. Exosomes (EXs) are highly heterogeneous bilayer vesicles that carry several molecule types in the extracellular space. The peculiarity is that they may be released from different cells and may be able to induce direct or indirect stimulation of the immune system. In particular, EX-based vaccines may cause an anti-tumor immune attack or produce memory cells recognizing cancer antigens and inhibiting disease development. This review delves into EX composition, biogenesis, and immune-modulating properties, exploring their role as a tool for prevention and therapy in solid tumors. Finally, we describe future research directions to optimize vaccine efficacy and realize the full potential of EX-based cancer immunotherapy.
Cancer remains one of the main causes of death in the world due to its increasing incidence and treatment difficulties. Although significant progress has been made in this field, innovative approaches are needed to reduce tumor incidence, progression, and spread. In particular, the development of cancer vaccines is currently ongoing as both a preventive and therapeutic strategy. This concept is not new, but few vaccines have been approved in oncology. Antigen-based vaccination emerges as a promising strategy, leveraging specific tumor antigens to activate the immune system response. However, challenges persist in finding suitable delivery systems and antigen preparation methods. Exosomes (EXs) are highly heterogeneous bilayer vesicles that carry several molecule types in the extracellular space. The peculiarity is that they may be released from different cells and may be able to induce direct or indirect stimulation of the immune system. In particular, EX-based vaccines may cause an anti-tumor immune attack or produce memory cells recognizing cancer antigens and inhibiting disease development. This review delves into EX composition, biogenesis, and immune-modulating properties, exploring their role as a tool for prevention and therapy in solid tumors. Finally, we describe future research directions to optimize vaccine efficacy and realize the full potential of EX-based cancer immunotherapy.
Exosome-like Systems: From Therapies to Vaccination for Cancer Treatment and Prevention—Exploring the State of the Art
No results. |
62 views. Last view on Monday 14 October 2024, 12:33:47
ibb.cnr.it
